Neurology News

The FDA has granted fast track designation to Avidity Biosciences Inc. for its novel RNA therapeutic AOC 1020, an antibody oligonucleotide conjugate being studied for the treatment of facioscapulohumeral muscular dystrophy.

U.K.-based biotechnology company Pheno Therapeutics announced it has entered into an exclusive worldwide license agreement with Belgian-based biopharmaceutical company UCB to deliver new therapeutics for neurodegenerative disease.

In this episode, Dr. Benjamin Claytor walks us through his approach to suspected sensory ganglionopathies. I also cover other neurologic complications of Sjogren’s syndrome and some interesting history on vitamin B6.

Amylyx Pharmaceuticals Inc. announced an exclusive license and distribution agreement with Neopharm for the commercialization of ALS therapeutic AMX0035 in Israel, Gaza, West Bank and the Palestinian Authority.

Health officials said a safety signal detected by a national surveillance system is “very unlikely” to represent a “true clinical risk” for stroke among older people who received the Pfizer-BioNTech bivalent COVID-19 booster.

Quantitative pupillometry may be a reliable method of assessing clinically intoxicated patients in EDs, per a study published in the Journal of the American College of Emergency Physicians Open.

LinusBio announced it has raised over $16 million in Series A funding to deliver technology that combines genomics, the environment and biological response to help diagnose and monitor the progression of disorders such as ALS and autism.

Treatment with IV Tenecteplase was not associated with better functional outcome after 90 days in patients with wake-up stroke selected using advanced imaging, per a study published in The Lancet Neurology.

Cerveau Technologies Inc. announced a partnership with Othair Prothena Limited, which will allow Prothena to use Cerveau’s investigational imaging agent in positron emission tomography scans to assess neurofibrillary tangles in the brain.

Myrtelle Inc. announced updated findings of the open-label phase 1/2 clinical trial of its recombinant adeno-associated virus vector-based investigational gene therapy for Canavan disease, a fatal genetic disorder in children.